Oral Wegovy Pill (25 mg): What the FDA Approval Means

For years, the catch with semaglutide was that the version that actually worked for weight loss came as a weekly shot. On December 22, 2025, that changed: the FDA approved a once-daily oral semaglutide 25 mg tablet — branded as the Wegovy pill — for chronic weight management¹. It is the first oral GLP-1 medicine approved for obesity in the United States¹. If you have already heard of "the semaglutide pill," though, you may be picturing Rybelsus, which is a different product entirely. Here is what the new pill is, what its trial actually showed, and why it is not the same thing as Rybelsus.

What the FDA actually approved

The new approval is for oral semaglutide at a 25 mg once-daily dose, marketed under the Wegovy brand, as an adjunct to a reduced-calorie diet and increased physical activity for adults with obesity, or overweight with at least one weight-related condition. It is also approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease¹. In plain terms: it is the obesity-dose semaglutide you previously could only get as an injection, now in a tablet — not a low-dose diabetes pill borrowed for off-label use.

That distinction matters because semaglutide already existed in pill form before this. Rybelsus, approved back in 2019, is oral semaglutide too — but it is approved only for blood-sugar control in type 2 diabetes, tops out at 14 mg, and is not approved for weight loss². We unpack that product in detail in Rybelsus (oral semaglutide): does the pill work for weight loss?. The new oral Wegovy is a higher dose with a dedicated obesity indication. Same molecule, very different regulatory standing.

What OASIS-4 showed

The approval rested largely on OASIS-4, a phase 3 trial published in the New England Journal of Medicine in 2025³. It randomized 307 adults with obesity, or overweight with weight-related complications — and notably without diabetes — to once-daily oral semaglutide 25 mg or placebo over 64 weeks (which included a roughly 12-week dose-escalation period)³.

The headline number you will see quoted is 16.6% average weight loss. That figure describes the effect when participants stayed on treatment as intended, versus about 2.7% on placebo¹³. Roughly one in three people on the drug lost 20% or more of their body weight¹. Those are obesity-injection-class results from a tablet — which is the genuinely new part of this story.

A few honest caveats keep that number in proportion. OASIS-4 was a relatively small trial (307 people) over a defined window, and the 16.6% reflects on-treatment adherence rather than a guarantee for everyone who fills a prescription. As with all GLP-1 medicines, results depend on actually reaching and tolerating the target dose, and weight tends to return when the drug is stopped — a pattern we cover in what happens if you stop semaglutide?.

Why the 25 mg pill ≠ the 14 mg Rybelsus pill

This is the single most common point of confusion, so it is worth being precise. Both Rybelsus and oral Wegovy are oral semaglutide. The reason they behave so differently comes down to dose and absorption.

Semaglutide is a peptide, and the stomach normally destroys peptides. Oral semaglutide gets around this with an absorption enhancer, but only a small, variable fraction of each tablet is actually absorbed — which is why oral doses have to be far larger than the injection to reach comparable blood levels. Rybelsus is capped at 14 mg, a diabetes dose that produces only modest weight loss². Oral Wegovy is 25 mg with a dedicated obesity trial behind it. So the dramatic OASIS-4 numbers belong to the 25 mg obesity product — not to the 14 mg Rybelsus tablet a pharmacy dispenses for diabetes. (For more on why swallowed semaglutide is finicky dose-for-dose, see oral vs injectable semaglutide.)

The dosing rules are still strict

The absorption problem also dictates how the pill must be taken, and these rules are not optional fine print. Like Rybelsus, oral semaglutide must be taken on an empty stomach right after waking, with no more than about 4 ounces of plain water, followed by a wait of at least 30 minutes before eating, drinking anything else, or taking other oral medicines; the tablet is swallowed whole². Breaking these rules — taking it with food or extra water — meaningfully lowers how much drug is absorbed, which can blunt the very effect you are paying for. A pill is more convenient than a needle, but only if the timing discipline is followed.

Side effects and cautions: the same GLP-1 family

Because it is the same molecule acting on the same GLP-1 receptors, oral Wegovy carries the same side-effect profile as injectable semaglutide — most commonly nausea, vomiting, diarrhea, and constipation, which tend to be worst during dose escalation and ease over time². It also carries the same class-level cautions, including the boxed warning about thyroid C-cell tumors seen in rodents and a contraindication in people with a personal or family history of medullary thyroid carcinoma². There is also a separately tracked, very rare eye-nerve signal (NAION) now noted by regulators for semaglutide medicines, which we cover in semaglutide and NAION (vision risk). This is a prescription-only medicine, not a casual supplement. For managing the gut symptoms through titration, see semaglutide dosing & side effects.

So what does the approval actually mean for you?

Practically, it means there is now a needle-free way to get obesity-dose semaglutide with real trial evidence behind it — a meaningful option for people who cannot or will not inject. But it does not mean the pill is automatically the right choice. The injectable Wegovy still has the larger and longer evidence base, and the daily empty-stomach routine of the oral version is a real commitment. Cost and coverage will also shape the decision, since GLP-1 medicines are expensive and insurance for obesity treatment is uneven — we track that in Wegovy cost & savings and does insurance cover Wegovy and Ozempic?. (And note that the cheap "compounded semaglutide" route that filled the gap during the shortage has largely closed — see is compounded semaglutide still legal in 2026?.) For how the semaglutide options stack up overall, see our best semaglutide guide, and for the full picture of how the drug works, our pillar, Semaglutide: how it works, results & side effects.